… -small cell lung carcinoma and the response to erlotinib therapy. J Cancer Res Ther 2020;16…
-generation reversible EGFR TKIs including gefitinib and erlotinib, the second-generation …

… The network meta-analysis from randomized phase III control trials showed no significant
differences in efficacy between afatinib gefitinib, erlotinib, and icotinib (13). Although 2-year OS …

… Methods: In this non-interventional, global, multi-centre study (NCT04179890), existing … pts
with uncommon EGFR mutations treated with either erlotinib, gefitinib, afatinib or osimertinib. …

… Early clinical trials of postoperative adjuvant erlotinib/gefitinib for patients with resected …
gefitinib group withdrew consent to use any of their data and were excluded from the ITT cohort…

… A cohort study of Anlotinib plus Erlotinib has shown a favorable safety profile and promising
… III study aims to evaluate the efficacy and safety of Anlotinib or placebo plus Gefitinib in …

… Tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are usually recommended
for patients with common … Table 1 summarizes the patient characteristics of the study cohort. …

… JO25567 study revealed that bevacizumab plus erlotinib may … were two cohorts: Cohort A:
apatinib 500 mg + gefitinib 250 … Cohort B: apatinib 250 mg + gefitinib 250 mg that was taken at …

… generation EGFR TKIs such as erlotinib, gefitinib, and afatinib became the standard for first
line EGFRmt NSCLC patients, following a series of positive studies comparing TKI to first line …

… In the current study, however, we compared afatinib to pooled data for gefitinib and erlotinib.
Second, in this study, the patients who received afatinib had better performance statuses …

… plus erlotinib combination therapy demonstrated improved PFS compared with erlotinib
alone for … We speculated this could be attributed to the fact that a cohort of patients with poor …